Zalcitabine Articles
TheraQuest's TQ-1019 shows sustained efficacy in animals
1 September 2008
WHO recommends AIDS drugs, makers
1 April 2002
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
FDA Approves Isis And CIBA Vision's Vitravene
1 September 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
HIVID Combination Gets EU Approval
4 December 1997
Roche's Invirase Confers Survival Benefit
20 October 1997
Roche Shows Three HIV Drugs Cut AIDS Onset
26 June 1997
Spanish Health Care Spending On AIDS
13 January 1997
Delavirdine Filed In USA; NNRTI Role Reviewed
29 July 1996
Ritonavir Triple Therapy
29 July 1996
Lamivudine Study Halted Early On Ethical Grounds
29 July 1996
Liposomal Delivery Of Antivirals
29 July 1996
1996 First-Half Sales In Line At Roche
22 July 1996
CPMP Positive On Roche's Invirase
1 July 1996
Antivirals "Now 9% Of Anti-Infectives Market"
11 March 1996
Norvir Launch Soon As FDA Clears 2nd Protease Inhibitor
11 March 1996
Moves In HIV Therapy As FDA Panel Delivers Verdicts
4 March 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Fast Growth Forecast For Antivirals
30 October 1995
Delta Trial Gives Boost To AIDS Community
2 October 1995
B-MS Shows Benefits Of Antiretroviral Therapy
25 September 1995
Roche Ahead Of Forecasts in 1995 First Half
4 September 1995
Glaxo Wellcome Files First Dossier For 3TC
10 July 1995
Expanded Access Urged For Protease Inhibitors
13 March 1995
Lamivudine/Zidovudine Combination Promising
13 February 1995
Lamivudine In AIDS: Ph II/III Results
6 February 1995
Lamivudine Enhances Zidovudine Efficacy
28 November 1994
HIV Therapy Options Examined
31 October 1994
Hivid Approved In UK
19 September 1994
Phase II Data On Saquinavir
12 September 1994
HIVID Approved For Monotherapy In USA
15 August 1994
Wellcome Details HIV Research Plans
15 August 1994
French Antiviral PB-100 Ruled As Ineffective
25 July 1994
PROMPT APPROVAL OF B-MS' STAVUDINE
4 July 1994
ROCHE ACCELERATES SAQUINAVIR FILING
13 June 1994
US FDA COMMITTEE COMMENTS ON STAVUDINE
30 May 1994
FIRMS TO SHARE AIDS DRUG TRIAL DATA
25 April 1994
HIVID AS EFFECTIVE AS VIDEX
21 March 1994
ZALCITABINE AS EFFECTIVE AS DIDANOSINE
14 March 1994
PROTEINASE INHIBITOR IN PHASE III TESTING
7 February 1994
CALL FOR US FDA AIDS DRUG COMMITTEE
7 February 1994
ROCHE RECORDS 11% INCREASE IN '93 SALES
17 January 1994
INCREASE IN NEW AIDS drugs IN TRIALS IN USA FOR 1993
10 January 1994
ORPHAN DRUG DESIGNATIONS IN JAPAN
20 December 1993
JAPAN DESIGNATES 40 ORPHAN DRUGS
29 November 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
FIALURIDINE TRIAL CASE HOTS UP
1 November 1993
ROCHE RAISES $702 MILLION IN US PLACEMENT
4 October 1993
US PANEL BACKS HIVID AS MONOTHERAPY...
4 October 1993
SINGAPORE CHARITY BUYS AIDS DRUGS
20 September 1993
COMBINATION THERAPIES IN AIDS: LITTLE PROGRESS
21 June 1993
ROCHE FORESEES GOOD OUTLOOK FOR 1993
3 May 1993
LARGE-SCALE US TB TRIAL PLANNED
26 April 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
US HIV-TRIAL FOR ROCHE'S RO 31-8959
5 April 1993
JANSSEN TO PRESS ON WITH R 89439 DEV'T
8 March 1993
ROCHE UNDER FIRE FROM AIDS ACTIVIST GROUPS
15 February 1993
HIVID AND VIDEX SHOW SIMILAR BENEFITS
1 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
FURTHER ANTIVIRAL EFFECT OF RETROVIR?
25 January 1993
ACCELERATED APPRO RULES DUE FROM FDA
14 December 1992
NEW DRUGS HIGHLIGHTED AT AIDS CONFERENCE
3 August 1992
ROCHE'S HIVID GETS APPROVAL IN USA
29 June 1992
LIMITED US APPROVAL RECOMMENDED FOR HIVID
27 April 1992
STOCK MARKET COMMENTARY: EUROPE
20 April 1992
HIV POPULATIONS "ARE STABILIZING"
17 February 1992
US FDA BANS COPIED ZALCITABINE
17 February 1992
HIVID TRIAL SETBACK NOT SERIOUS, SAYS ROCHE
3 February 1992
ROCHE HALTS ZALCITABINE TRIAL
27 January 1992
ROCHE SEES SALES INCREASE 19% IN 1991
20 January 1992
AIDS MONOTHERAPIES COMPARED
20 January 1992
Showing 1-76 of 76 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
